CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy–Resistant Glioblastoma

• Published in: Neoplasia (New York, N.Y.) N.Y.), 2018-10, Vol.20 (10), p.1070-1082
• Main Authors: Angara, Kartik, Borin, Thaiz F., Rashid, Mohammad H., Lebedyeva, Iryna, Ara, Roxan, Lin, Ping-Chang, Iskander, ASM, Bollag, Roni J., Achyut, Bhagelu R., Arbab, Ali S.
• Format: Article
• Language: English
• Subjects: Angiogenesis Inhibitors - pharmacology; Animal models; Animals; Bevacizumab - pharmacology; Brain Neoplasms - blood supply; Brain Neoplasms - drug therapy; Brain Neoplasms - pathology; Brain tumors; Clinical trials; CXCR2 protein; Glioblastoma; Glioblastoma - blood supply; Glioblastoma - drug therapy; Glioblastoma - pathology; Glioma cells; Humans; Interleukin 8; Interleukin-8 - metabolism; Mimicry; Molecular Targeted Therapy - methods; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - metabolism; Original article; Phenotypes; Phenylurea Compounds - pharmacology; Phthalazines - pharmacology; Pyridines - pharmacology; Rats, Nude; Receptors, Interleukin-8B - genetics; Receptors, Interleukin-8B - metabolism; Stem cell transplantation; Stem cells; Tissue Array Analysis; Tumor Burden; Tumor cells; Tumors; Vascular endothelial growth factor; Vascularization; Xenograft Model Antitumor Assays
• ISSN: 1476-5586; 1522-8002; 1476-5586
• DOI: 10.1016/j.neo.2018.08.011

BACKGROUND: Glioblastoma (GBM) was shown to relapse faster and displayed therapeutic resistance to antiangiogenic therapies (AATs) through an alternative tumor cell-driven mechanism of neovascularization called vascular mimicry (VM). We identified highly upregulated interleukin 8 (IL-8)-CXCR2 axis in tumor cells in high-grade human glioma and AAT-treated orthotopic GBM tumors. METHODS: Human GBM tissue sections and tissue array were used to ascertain the clinical relevance of CXCR2-positive tumor cells in the formation of VM. We utilized U251 and U87 human tumor cells to understand VM in an orthotopic GBM model and AAT-mediated enhancement in VM was modeled using vatalanib (anti-VEGFR2) and avastin (anti-VEGF). Later, VM was inhibited by SB225002 (CXCR2 inhibitor) in a preclinical study. RESULTS: Overexpression of IL8 and CXCR2 in human datasets and histological analysis was identified as a bonafide candidate to validate VM through in vitro and animal model studies. AAT-treated tumors displayed a higher number of CXCR2-positive GBM-stem cells with endothelial-like phenotypes. Stable knockdown of CXCR2 expression in tumor cells led to decreased tumor growth as well as incomplete VM structures in the animal models. Similar data were obtained following SB225002 treatment. CONCLUSIONS: The present study suggests that tumor cell autonomous IL-8-CXCR2 pathway is instrumental in AAT-mediated resistance and VM formation in GBM. Therefore, CXCR2 can be targeted through SB225002 and can be combined with standard therapies to improve the therapeutic outcomes in clinical trials.